WAM
PTGX icon

Wolverine Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Wolverine Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-80,000
Closed -$968K – 1583
2019
Q2 		$968K Buy
+80,000
New +$884K 0.01% 665

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wolverine Asset Management's PTGX Position: Q3 2019 in Review

Wolverine Asset Management sold out of Protagonist Therapeutics (PTGX) in Q3 2019, closing a stake of 80,000 shares — an estimated $968K sold.

Wolverine Asset Management first reported a position in PTGX in Q2 2019 and held it in 1 quarter. The position peaked at $968K in Q2 2019. 76 funds tracked by Wall St. Rank hold PTGX as of Q3 2019.

  • Wolverine Asset Management reported no remaining Protagonist Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Wolverine Asset Management sold 80,000 Protagonist Therapeutics shares in Q3 2019, an estimated $968K.
  • Wolverine Asset Management first reported a position in Protagonist Therapeutics in Q2 2019 and held it in 1 quarter.
  • Wolverine Asset Management's Protagonist Therapeutics position peaked at $968K in Q2 2019.
  • 76 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2019.

Based on Wolverine Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.